Prospects Not Terminal for Endocyte's Cancer Drug Vintafolide

Following an interim analysis, Endocyte (ECYT-$11.40) reported last Thursday that the independent Drug Safety Monitoring Board (DSMB) advised investigators to tell non-small cell lung cancer patients enrolled in the TARGET study that vintafolide use in monotherapy was unlikely to prove superior to docetaxel in progression-free survival (PFS) at the termination of the study.

However, news that the DSMB observed the combo arm of the TARGET study (vintafolide & taxotere) was trending toward the statistical goal of a 50% improvement in PFS relative to the taxotere arm (and didn’t demonstrate any new safety concerns) ultimately could prove to be good tidings for Endocyte shareholders.

Read more at YCharts: Endocyte’s Plunge Ignores Drug’s $2.5B Potential

Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.